Mibolerone
From Wikipedia, the free encyclopedia
Mibolerone
|
|
Systematic (IUPAC) name | |
(7R,8R,9S,10R,13S,14S,17S)-17-Hydroxy- 7,13,17-trimethyl-1,2,6,7,8,9,10,11,1
2,14,15,16-dodecahydrocyclopenta[a]phenanthren-3-one |
|
Identifiers | |
CAS number | |
ATC code | ? |
PubChem | |
Chemical data | |
Formula | C20H30O2 |
Mol. mass | 302.4558 g/mol |
Pharmacokinetic data | |
Bioavailability | ? |
Metabolism | Hepatic |
Half life | 2-4 hours |
Excretion | ? |
Therapeutic considerations | |
Pregnancy cat. |
? |
Legal status |
Schedule 3 (US) |
Routes | Oral |
Mibolerone is a potent anabolic steroid which is both higher affinity[1] and more selective[2] for the androgen receptor than metribolone.
[edit] References
- ^ Murthy LR, Johnson MP, Rowley DR, Young CY, Scardino PT, Tindall DJ (1986). "Characterization of steroid receptors in human prostate using mibolerone". Prostate 8 (3): 241–53. PMID 2422638.
- ^ Schilling K, Liao S (1984). "The use of radioactive 7 alpha, 17 alpha-dimethyl-19-nortestosterone (mibolerone) in the assay of androgen receptors". Prostate 5 (6): 581–8. PMID 6333679.
|